We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tissue Regenix Group plc (TRX) Ordinary 0.1p

Sell:0.50p Buy:0.53p 0 Change: 0.009p (1.78%)
Market closed Prices as at close on 8 December 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.53p
Change: 0.009p (1.78%)
Market closed Prices as at close on 8 December 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.53p
Change: 0.009p (1.78%)
Market closed Prices as at close on 8 December 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.

Contact details

Address:
2 Astley Way
Astley Lane Industrial Estate
LEEDS
LS26 8XT
United Kingdom
Telephone:
+44 (01904) 567609
Website:
https://www.tissueregenix.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 08 September 2021 08/09/21
AGM 03 June 2021 03/06/21
Final results 28 April 2021 28/04/21
Trading Announcement 08 February 2021 08/02/21

General stock information

EPIC:
TRX
ISIN:
GB00B5SGVL29
Market cap:
£36.22 million
Shares in issue:
7.03 billion
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Daniel Lee
    Chief Executive Officer, Director
  • David Cocke
    Chief Financial Officer, Director
  • Kirsten Lund
    Group Finance Director, Company Secretary
  • Patti Gary
    Vice President - Clinical Affairs
  • Lance Johnson
    VP, Quality and Regulatory, US
  • Gerald Sharpe
    Vice President - Strategic Partnerships
  • Tina Trimble
    VP, Donor Services, US
  • Christine Rowley
    Technical and Operations Director, UK

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.